Iofina（IF7）株式概要イオフィナ・ピーエルシーは、その子会社とともに、米国および英国における石油・ガス事業からヨウ素およびハロゲンベースの特殊化学品誘導体の探査、開発、生産を行っている。 詳細IF7 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長2/6過去の実績5/6財務の健全性6/6配当金0/6報酬株価収益率（ 14.6 x） German市場（ 17.3 x）を下回っています。収益は年間21.29%増加すると予測されています 過去1年間で収益は169.6%増加しました リスク分析German市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見るIF7 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.4950.7% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-10m175m2016201920222025202620282031Revenue US$174.6mEarnings US$20.7mAdvancedSet Fair ValueView all narrativesFeatured narrative•Materials opportunityUpside Gold2 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 割安 内在価値ディスカウントAn Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative15.1kusers have viewed this narrative42users have liked this narrative1users have commented on this narrative287users have followed this narrativeRead narrativeIofina plc 競合他社NabaltecSymbol: XTRA:NTGMarket cap: €92.8mUzin UtzSymbol: XTRA:UZUMarket cap: €350.1mAlzChem GroupSymbol: XTRA:ACTMarket cap: €1.6bEvonik IndustriesSymbol: XTRA:EVKMarket cap: €7.9b価格と性能株価の高値、安値、推移の概要Iofina過去の株価現在の株価UK£0.4952週高値UK£0.5352週安値UK£0.22ベータ0.851ヶ月の変化80.74%3ヶ月変化76.81%1年変化96.77%3年間の変化37.85%5年間の変化339.64%IPOからの変化62.13%最新ニュースお知らせ • May 05Iofina plc, Annual General Meeting, Jun 09, 2026Iofina plc, Annual General Meeting, Jun 09, 2026. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdomお知らせ • Apr 16Iofina plc Provides Production Guidance for the First Half of Fiscal Year 2026Iofina plc provided production guidance for the first half of fiscal year 2026. For the period, The Company now expects to exceed the previous H1 2026 production guidance of 325MT-355MT. Based on the current trends, the Company is now anticipating H1 2026 production to be closer to 385MT.お知らせ • Jan 13Iofina plc Provides Earnings Guidance for 2025 and Production Guidance for the First Half of 2026Iofina plc provided earnings guidance for 2025 and production guidance for the first half of 2026. For the 2025, the company's revenue are projected to surpass $65 million. For the first half of 2026, the company expects to produce between 325 MT-355 MT of crystalline iodine in H1 2026 (H1 2025: 305.5MT).お知らせ • Dec 14Iofina plc Announces the Proposed Appointment of Tim Hughes as a Non-Executive Director, Effective 1 January 2026Iofina plc announced the proposed appointment of Tim Hughes as a Non-Executive Director, to take effect from 1 January 2026. Tim has significant experience in general management in the specialty chemical industry as well as corporate and sustainability matters. Tim was a member of the Executive Committee of Synthomer plc for 11 years until 2023 as divisional director for the industrial specialties global business, which included the company's specialty iodine business, before then becoming President of Corporate Development, where he was responsible for investor relations, external affairs and the development of the company's sustainability strategy. Prior to Synthomer, Tim led the Urethane Technologies joint venture business for Chemtura Corporation and spent 14 years in business leadership and marketing roles at Courtaulds plc. Tim is based in the UK and holds a BSc in Chemistry from the University of Manchester and an MBA from Cranfield University. Concurrent with his appointment, Tim will also be appointed as a member of Iofina's Audit and Remuneration Committees. Timothy John Hughes, age 61, is currently or has been a Director of the following companies within the past five years: Current Directorships at Catalyst Science Discovery Centre and Museum Trust Limited, Synthomer (UK) Limited and Chemical Industries Association Limited and Previous Directorships at Synthomer (UK) Limited.お知らせ • Oct 17Iofina plc Provides Production Guidance for the Second Half of 2025Iofina plc provided production guidance for the second half of 2025. For the period, the company expects production is on track to be within the production range of 400 MT - 440 MT.お知らせ • May 15Iofina plc, Annual General Meeting, Jun 09, 2025Iofina plc, Annual General Meeting, Jun 09, 2025. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdom最新情報をもっと見るRecent updatesお知らせ • May 05Iofina plc, Annual General Meeting, Jun 09, 2026Iofina plc, Annual General Meeting, Jun 09, 2026. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdomお知らせ • Apr 16Iofina plc Provides Production Guidance for the First Half of Fiscal Year 2026Iofina plc provided production guidance for the first half of fiscal year 2026. For the period, The Company now expects to exceed the previous H1 2026 production guidance of 325MT-355MT. Based on the current trends, the Company is now anticipating H1 2026 production to be closer to 385MT.お知らせ • Jan 13Iofina plc Provides Earnings Guidance for 2025 and Production Guidance for the First Half of 2026Iofina plc provided earnings guidance for 2025 and production guidance for the first half of 2026. For the 2025, the company's revenue are projected to surpass $65 million. For the first half of 2026, the company expects to produce between 325 MT-355 MT of crystalline iodine in H1 2026 (H1 2025: 305.5MT).お知らせ • Dec 14Iofina plc Announces the Proposed Appointment of Tim Hughes as a Non-Executive Director, Effective 1 January 2026Iofina plc announced the proposed appointment of Tim Hughes as a Non-Executive Director, to take effect from 1 January 2026. Tim has significant experience in general management in the specialty chemical industry as well as corporate and sustainability matters. Tim was a member of the Executive Committee of Synthomer plc for 11 years until 2023 as divisional director for the industrial specialties global business, which included the company's specialty iodine business, before then becoming President of Corporate Development, where he was responsible for investor relations, external affairs and the development of the company's sustainability strategy. Prior to Synthomer, Tim led the Urethane Technologies joint venture business for Chemtura Corporation and spent 14 years in business leadership and marketing roles at Courtaulds plc. Tim is based in the UK and holds a BSc in Chemistry from the University of Manchester and an MBA from Cranfield University. Concurrent with his appointment, Tim will also be appointed as a member of Iofina's Audit and Remuneration Committees. Timothy John Hughes, age 61, is currently or has been a Director of the following companies within the past five years: Current Directorships at Catalyst Science Discovery Centre and Museum Trust Limited, Synthomer (UK) Limited and Chemical Industries Association Limited and Previous Directorships at Synthomer (UK) Limited.お知らせ • Oct 17Iofina plc Provides Production Guidance for the Second Half of 2025Iofina plc provided production guidance for the second half of 2025. For the period, the company expects production is on track to be within the production range of 400 MT - 440 MT.お知らせ • May 15Iofina plc, Annual General Meeting, Jun 09, 2025Iofina plc, Annual General Meeting, Jun 09, 2025. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdomお知らせ • Apr 19Iofina plc Revises Production Guidance for First Half of 2025Iofina plc revised production guidance for first half of 2025. For the period, the company now expects total iodine production for first half of 2025 to be closer to 300MT compared to the previously guided range of 320MT-355MT. The company will provide a further update on Iofina Resources' production as part of its year-end 2024 financial reporting.Reported Earnings • Sep 26First half 2024 earnings released: EPS: US$0.003 (vs US$0.019 in 1H 2023)First half 2024 results: EPS: US$0.003 (down from US$0.019 in 1H 2023). Revenue: US$26.0m (up 6.9% from 1H 2023). Net income: US$607.0k (down 83% from 1H 2023). Profit margin: 2.3% (down from 15% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.お知らせ • Jul 16Iofina plc Provides Production Guidance for the Second Half of 2024Iofina plc provided production guidance for the second half of 2024. The company anticipates production in the second half of 2024 to be in the range of 355 MT - 380 MT.New Risk • Jun 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (€47.3m market cap, or US$50.8m).Buy Or Sell Opportunity • Jun 13Now 33% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to €0.22. The fair value is estimated to be €0.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 29%.お知らせ • May 17Iofina plc, Annual General Meeting, Jun 13, 2024Iofina plc, Annual General Meeting, Jun 13, 2024. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdomお知らせ • May 16Iofina plc Announces Resignation of William ("Bill") D. Bellamy as DirectorIofina plc announced that Dr. William ("Bill") D. Bellamy, Chair of the Remuneration Committee, will retire as a Director of the Company at the close of the AGM and is therefore not being submitted for re-appointment in the business of the meeting.Reported Earnings • May 03Full year 2023 earnings released: EPS: US$0.034 (vs US$0.041 in FY 2022)Full year 2023 results: EPS: US$0.034 (down from US$0.041 in FY 2022). Revenue: US$50.0m (up 19% from FY 2022). Net income: US$6.56m (down 17% from FY 2022). Profit margin: 13% (down from 19% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year whereas the company’s share price has increased by 25% per year.New Risk • Apr 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€47.2m market cap, or US$50.2m).New Risk • Mar 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€49.4m market cap, or US$53.2m).お知らせ • Jan 15Iofina plc Provides Market Update Regarding Its Activities During Fourth Quarter 2023 and Outlines Expectations for 2024Iofina plc provided a market update regarding its activities during Fourth Quarter 2023 and outlines expectations for 2024. With IO#9 plant operating at an improved production rate in the second half of Fourth Quarter 2023,crystalline iodine production across Iofina Resources' six plants for the last quarter increased year over year by 16% to 160.9 metric tonnes (MT). Total production during the second half was 317.8MT, which aligned with the Company's guidance that H2 2023 production would either be at the bottom or very marginally below the forecast range of 325-350MT. This nevertheless represents a13% increase over production of 282.0MT for H2 2022. Total crystalline iodine production in 2023 was up 8% to 559.3MT, compared to 2022 production levels of 516MT. The iodine spot price softened by circa five percent over H2 2023 towards mid-to-upper sixties dollars per kilogram as prices have settled from historically high levels. Moving into 2024, the market fundamentals of the iodine business remain strong and Iofina currently expects the spot price to remain at present levels for the foreseeable future. Demand for the Company's crystalline iodine remained robust during the final quarter, whilst sales of iodine derivatives had mixed results. Regarding non-iodine products, sales of a key product mainly used in the semiconductor industry improved significantly in the second half of the year after a slower-than-anticipated first half. Moving into 2024, Iofina Resources expects to produce 275MT - 295MT of crystalline iodine during the first half (H1 2023: 242MT), which would result in a 13% to 22% increase over H1 2023. The Company reiterates that H1 iodine plant production has historically always been lower than H2 production due to the effect of lower temperatures on production in the winter months, whereas H2 production benefits from greater output in the warmer summer period. Encouraging progress has also been made regarding construction plans for IO#10 plant, with groundwork at the site scheduled to commence this week. The Company expects IO#10 iodine production to commence in Third Quarter 2024 and will update on progress as appropriate. Negotiations continue to progress well with both current and potential new brine supply partners for IO#11, and the Company continues to explore options in its current core area and other new areas for next iodine production facilities. In terms of new products, Iofina Chemical will beadding to its iodine derivatives product range in H1 2024, including an existing product in the market for which there is strong demand. The Company also expects to increase sales of its crystalline iodine to customers in Europe in 2024 through existing and new relationships. The Group is committed to operating its facilities with a safety-first approach and is proud to report that Iofina has had no lost time incidents since April 2021.お知らせ • Oct 20Iofina plc Provides Production Guidance for the Second Half of 2023Iofina plc provided production guidance for the second half of 2023. the company expected second half production is trending towards the lower end of company's forecast of 325-350 MT.Reported Earnings • Sep 15First half 2023 earnings released: EPS: US$0.019 (vs US$0.01 in 1H 2022)First half 2023 results: EPS: US$0.019 (up from US$0.01 in 1H 2022). Revenue: US$24.3m (up 27% from 1H 2022). Net income: US$3.56m (up 85% from 1H 2022). Profit margin: 15% (up from 10.0% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.7% p.a. on average during the next 2 years, compared to a 2.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 12Iofina plc Provides Production Guidance for the Second Half of 2023Iofina plc provided production guidance for the second half of 2023. With the addition of IO#9 output, second half 2023 production is on track to meet the 325-350MT target.New Risk • Jul 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (€68.5m market cap, or US$76.6m).お知らせ • May 09Iofina plc, Annual General Meeting, Jun 14, 2023Iofina plc, Annual General Meeting, Jun 14, 2023, at 09:00 Coordinated Universal Time. Location: Canaccord Genuity, 88 Wood Street London United Kingdom Agenda: To receive and adopt the reports of the directors and the auditors and the audited financial statements of the Company for the year ended 31 December 2022; to re-appoint Malcolm Lewin as director; to re-appoint Mary Fallin Christensen as a director; to re-appoint UHY Hacker Young LLP as the Company's auditors to hold office from the conclusion of the AGM to the conclusion of the next meeting at which the accounts are laid before the Company and to authorise the directors to determine remuneration.Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Mary Christensen was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 26Full year 2022 earnings released: EPS: US$0.041 (vs US$0.048 in FY 2021)Full year 2022 results: EPS: US$0.041 (down from US$0.048 in FY 2021). Revenue: US$42.2m (up 8.1% from FY 2021). Net income: US$7.87m (down 14% from FY 2021). Profit margin: 19% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.Reported Earnings • Sep 27First half 2022 earnings released: EPS: US$0.01 (vs US$0.018 in 1H 2021)First half 2022 results: EPS: US$0.01 (down from US$0.018 in 1H 2021). Revenue: US$19.2m (down 3.8% from 1H 2021). Net income: US$1.93m (down 45% from 1H 2021). Profit margin: 10.0% (down from 18% in 1H 2021). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 1.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • May 27Iofina plc, Annual General Meeting, Jun 22, 2022Iofina plc, Annual General Meeting, Jun 22, 2022, at 09:00 Coordinated Universal Time. Location: One Bartholomew Close, London EC1A 7BL London United KingdomReported Earnings • May 10Full year 2021 earnings released: EPS: US$0.048 (vs US$0.007 in FY 2020)Full year 2021 results: EPS: US$0.048 (up from US$0.007 in FY 2020). Revenue: US$39.0m (up 32% from FY 2020). Net income: US$9.19m (up US$7.91m from FY 2020). Profit margin: 24% (up from 4.3% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.3%, compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Buying Opportunity • Jan 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 3.2%. The fair value is estimated to be US$0.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% per annum over the last 3 years. The company has become profitable over the last 3 years.お知らせ • Jan 18Iofina plc Provides Production Guidance for the First Half of 2022Iofina plc provided production guidance for the first half of 2022. For the period, the company forecasted production figure of 225-240MT of crystalline iodine.Reported Earnings • Sep 26First half 2021 earnings released: EPS US$0.018 (vs US$0.007 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$19.9m (up 27% from 1H 2020). Net income: US$3.50m (up 164% from 1H 2020). Profit margin: 18% (up from 8.4% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 134% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 15Iofina plc Provides Production Guidance for the Second Half of 2021Iofina plc provided production guidance for the second half of 2021. For the period, the company is anticipating iodine production of 260-275 metric tonnes ("MT") , with operational changes at a brine partner's sites affecting supply levels to two of plants this year.Reported Earnings • May 27Full year 2020 earnings released: EPS US$0.007 (vs US$0.003 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$29.7m (up 1.5% from FY 2019). Net income: US$1.28m (up 131% from FY 2019). Profit margin: 4.3% (up from 1.9% in FY 2019). Over the last 3 years on average, earnings per share has increased by 126% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Apr 15Iofina plc Revises Production Guidance for the First Half of 2021Iofina plc revised production Guidance for the first half of 2021. For the period, the company now expect production of approximately 250MT, below the 285-305 MT forecast.株主還元IF7DE ChemicalsDE 市場7D38.6%-3.9%-0.02%1Y96.8%2.2%0.1%株主還元を見る業界別リターン: IF7過去 1 年間で2.2 % の収益を上げたGerman Chemicals業界を上回りました。リターン対市場: IF7過去 1 年間で0.1 % の収益を上げたGerman市場を上回りました。価格変動Is IF7's price volatile compared to industry and market?IF7 volatilityIF7 Average Weekly Movement17.1%Chemicals Industry Average Movement5.6%Market Average Movement6.0%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.6%安定した株価: IF7の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: IF7の 週次ボラティリティ は、過去 1 年間で12%から17%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2005116Tom Beckeriofina.comイオフィナ・ピーエルシーは、その子会社とともに、米国と英国の石油・ガス事業からヨウ素とハロゲンベースの特殊化学品誘導体の探索、開発、生産を行っている。同社は、ハロゲン化学品、殺菌剤、電子特殊ガス、除菌剤、熱安定剤、防腐剤、特殊中間体、動物用薬品、鉱物分離、臭気制御製品を提供している。同社の製品は、エレクトロニクス/半導体、製薬、食品・飲料、パーソナルケア、塗料・コーティング、乳製品、化学中間体、宝石、魚類・野生動物、ナイロンの各市場で使用されている。同社はイオフロとイオプリルのブランド名で製品を販売している。イオフィナ・ピーエルシーは2005年に設立され、英国ロンドンに本社を置く。もっと見るIofina plc 基礎のまとめIofina の収益と売上を時価総額と比較するとどうか。IF7 基礎統計学時価総額€98.08m収益（TTM）€6.70m売上高(TTM)€56.66m14.6xPER（株価収益率1.7xP/SレシオIF7 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計IF7 損益計算書（TTM）収益US$66.52m売上原価US$48.48m売上総利益US$18.03mその他の費用US$10.17m収益US$7.87m直近の収益報告Dec 31, 2025次回決算日May 13, 2026一株当たり利益（EPS）0.041グロス・マージン27.11%純利益率11.83%有利子負債／自己資本比率11.7%IF7 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 17:19終値2026/05/07 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Iofina plc 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Alexander BrooksCanaccord GenuityStuart JoynerInvestec Bank plc (UK)
Featured narrative•Materials opportunityUpside Gold2 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 割安 内在価値ディスカウントAn Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative15.1kusers have viewed this narrative42users have liked this narrative1users have commented on this narrative287users have followed this narrativeRead narrative
お知らせ • May 05Iofina plc, Annual General Meeting, Jun 09, 2026Iofina plc, Annual General Meeting, Jun 09, 2026. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdom
お知らせ • Apr 16Iofina plc Provides Production Guidance for the First Half of Fiscal Year 2026Iofina plc provided production guidance for the first half of fiscal year 2026. For the period, The Company now expects to exceed the previous H1 2026 production guidance of 325MT-355MT. Based on the current trends, the Company is now anticipating H1 2026 production to be closer to 385MT.
お知らせ • Jan 13Iofina plc Provides Earnings Guidance for 2025 and Production Guidance for the First Half of 2026Iofina plc provided earnings guidance for 2025 and production guidance for the first half of 2026. For the 2025, the company's revenue are projected to surpass $65 million. For the first half of 2026, the company expects to produce between 325 MT-355 MT of crystalline iodine in H1 2026 (H1 2025: 305.5MT).
お知らせ • Dec 14Iofina plc Announces the Proposed Appointment of Tim Hughes as a Non-Executive Director, Effective 1 January 2026Iofina plc announced the proposed appointment of Tim Hughes as a Non-Executive Director, to take effect from 1 January 2026. Tim has significant experience in general management in the specialty chemical industry as well as corporate and sustainability matters. Tim was a member of the Executive Committee of Synthomer plc for 11 years until 2023 as divisional director for the industrial specialties global business, which included the company's specialty iodine business, before then becoming President of Corporate Development, where he was responsible for investor relations, external affairs and the development of the company's sustainability strategy. Prior to Synthomer, Tim led the Urethane Technologies joint venture business for Chemtura Corporation and spent 14 years in business leadership and marketing roles at Courtaulds plc. Tim is based in the UK and holds a BSc in Chemistry from the University of Manchester and an MBA from Cranfield University. Concurrent with his appointment, Tim will also be appointed as a member of Iofina's Audit and Remuneration Committees. Timothy John Hughes, age 61, is currently or has been a Director of the following companies within the past five years: Current Directorships at Catalyst Science Discovery Centre and Museum Trust Limited, Synthomer (UK) Limited and Chemical Industries Association Limited and Previous Directorships at Synthomer (UK) Limited.
お知らせ • Oct 17Iofina plc Provides Production Guidance for the Second Half of 2025Iofina plc provided production guidance for the second half of 2025. For the period, the company expects production is on track to be within the production range of 400 MT - 440 MT.
お知らせ • May 15Iofina plc, Annual General Meeting, Jun 09, 2025Iofina plc, Annual General Meeting, Jun 09, 2025. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdom
お知らせ • May 05Iofina plc, Annual General Meeting, Jun 09, 2026Iofina plc, Annual General Meeting, Jun 09, 2026. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdom
お知らせ • Apr 16Iofina plc Provides Production Guidance for the First Half of Fiscal Year 2026Iofina plc provided production guidance for the first half of fiscal year 2026. For the period, The Company now expects to exceed the previous H1 2026 production guidance of 325MT-355MT. Based on the current trends, the Company is now anticipating H1 2026 production to be closer to 385MT.
お知らせ • Jan 13Iofina plc Provides Earnings Guidance for 2025 and Production Guidance for the First Half of 2026Iofina plc provided earnings guidance for 2025 and production guidance for the first half of 2026. For the 2025, the company's revenue are projected to surpass $65 million. For the first half of 2026, the company expects to produce between 325 MT-355 MT of crystalline iodine in H1 2026 (H1 2025: 305.5MT).
お知らせ • Dec 14Iofina plc Announces the Proposed Appointment of Tim Hughes as a Non-Executive Director, Effective 1 January 2026Iofina plc announced the proposed appointment of Tim Hughes as a Non-Executive Director, to take effect from 1 January 2026. Tim has significant experience in general management in the specialty chemical industry as well as corporate and sustainability matters. Tim was a member of the Executive Committee of Synthomer plc for 11 years until 2023 as divisional director for the industrial specialties global business, which included the company's specialty iodine business, before then becoming President of Corporate Development, where he was responsible for investor relations, external affairs and the development of the company's sustainability strategy. Prior to Synthomer, Tim led the Urethane Technologies joint venture business for Chemtura Corporation and spent 14 years in business leadership and marketing roles at Courtaulds plc. Tim is based in the UK and holds a BSc in Chemistry from the University of Manchester and an MBA from Cranfield University. Concurrent with his appointment, Tim will also be appointed as a member of Iofina's Audit and Remuneration Committees. Timothy John Hughes, age 61, is currently or has been a Director of the following companies within the past five years: Current Directorships at Catalyst Science Discovery Centre and Museum Trust Limited, Synthomer (UK) Limited and Chemical Industries Association Limited and Previous Directorships at Synthomer (UK) Limited.
お知らせ • Oct 17Iofina plc Provides Production Guidance for the Second Half of 2025Iofina plc provided production guidance for the second half of 2025. For the period, the company expects production is on track to be within the production range of 400 MT - 440 MT.
お知らせ • May 15Iofina plc, Annual General Meeting, Jun 09, 2025Iofina plc, Annual General Meeting, Jun 09, 2025. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdom
お知らせ • Apr 19Iofina plc Revises Production Guidance for First Half of 2025Iofina plc revised production guidance for first half of 2025. For the period, the company now expects total iodine production for first half of 2025 to be closer to 300MT compared to the previously guided range of 320MT-355MT. The company will provide a further update on Iofina Resources' production as part of its year-end 2024 financial reporting.
Reported Earnings • Sep 26First half 2024 earnings released: EPS: US$0.003 (vs US$0.019 in 1H 2023)First half 2024 results: EPS: US$0.003 (down from US$0.019 in 1H 2023). Revenue: US$26.0m (up 6.9% from 1H 2023). Net income: US$607.0k (down 83% from 1H 2023). Profit margin: 2.3% (down from 15% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
お知らせ • Jul 16Iofina plc Provides Production Guidance for the Second Half of 2024Iofina plc provided production guidance for the second half of 2024. The company anticipates production in the second half of 2024 to be in the range of 355 MT - 380 MT.
New Risk • Jun 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (€47.3m market cap, or US$50.8m).
Buy Or Sell Opportunity • Jun 13Now 33% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to €0.22. The fair value is estimated to be €0.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 29%.
お知らせ • May 17Iofina plc, Annual General Meeting, Jun 13, 2024Iofina plc, Annual General Meeting, Jun 13, 2024. Location: the offices of canaccord genuity, 88 wood street, ec2v 7qr, london United Kingdom
お知らせ • May 16Iofina plc Announces Resignation of William ("Bill") D. Bellamy as DirectorIofina plc announced that Dr. William ("Bill") D. Bellamy, Chair of the Remuneration Committee, will retire as a Director of the Company at the close of the AGM and is therefore not being submitted for re-appointment in the business of the meeting.
Reported Earnings • May 03Full year 2023 earnings released: EPS: US$0.034 (vs US$0.041 in FY 2022)Full year 2023 results: EPS: US$0.034 (down from US$0.041 in FY 2022). Revenue: US$50.0m (up 19% from FY 2022). Net income: US$6.56m (down 17% from FY 2022). Profit margin: 13% (down from 19% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year whereas the company’s share price has increased by 25% per year.
New Risk • Apr 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€47.2m market cap, or US$50.2m).
New Risk • Mar 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€49.4m market cap, or US$53.2m).
お知らせ • Jan 15Iofina plc Provides Market Update Regarding Its Activities During Fourth Quarter 2023 and Outlines Expectations for 2024Iofina plc provided a market update regarding its activities during Fourth Quarter 2023 and outlines expectations for 2024. With IO#9 plant operating at an improved production rate in the second half of Fourth Quarter 2023,crystalline iodine production across Iofina Resources' six plants for the last quarter increased year over year by 16% to 160.9 metric tonnes (MT). Total production during the second half was 317.8MT, which aligned with the Company's guidance that H2 2023 production would either be at the bottom or very marginally below the forecast range of 325-350MT. This nevertheless represents a13% increase over production of 282.0MT for H2 2022. Total crystalline iodine production in 2023 was up 8% to 559.3MT, compared to 2022 production levels of 516MT. The iodine spot price softened by circa five percent over H2 2023 towards mid-to-upper sixties dollars per kilogram as prices have settled from historically high levels. Moving into 2024, the market fundamentals of the iodine business remain strong and Iofina currently expects the spot price to remain at present levels for the foreseeable future. Demand for the Company's crystalline iodine remained robust during the final quarter, whilst sales of iodine derivatives had mixed results. Regarding non-iodine products, sales of a key product mainly used in the semiconductor industry improved significantly in the second half of the year after a slower-than-anticipated first half. Moving into 2024, Iofina Resources expects to produce 275MT - 295MT of crystalline iodine during the first half (H1 2023: 242MT), which would result in a 13% to 22% increase over H1 2023. The Company reiterates that H1 iodine plant production has historically always been lower than H2 production due to the effect of lower temperatures on production in the winter months, whereas H2 production benefits from greater output in the warmer summer period. Encouraging progress has also been made regarding construction plans for IO#10 plant, with groundwork at the site scheduled to commence this week. The Company expects IO#10 iodine production to commence in Third Quarter 2024 and will update on progress as appropriate. Negotiations continue to progress well with both current and potential new brine supply partners for IO#11, and the Company continues to explore options in its current core area and other new areas for next iodine production facilities. In terms of new products, Iofina Chemical will beadding to its iodine derivatives product range in H1 2024, including an existing product in the market for which there is strong demand. The Company also expects to increase sales of its crystalline iodine to customers in Europe in 2024 through existing and new relationships. The Group is committed to operating its facilities with a safety-first approach and is proud to report that Iofina has had no lost time incidents since April 2021.
お知らせ • Oct 20Iofina plc Provides Production Guidance for the Second Half of 2023Iofina plc provided production guidance for the second half of 2023. the company expected second half production is trending towards the lower end of company's forecast of 325-350 MT.
Reported Earnings • Sep 15First half 2023 earnings released: EPS: US$0.019 (vs US$0.01 in 1H 2022)First half 2023 results: EPS: US$0.019 (up from US$0.01 in 1H 2022). Revenue: US$24.3m (up 27% from 1H 2022). Net income: US$3.56m (up 85% from 1H 2022). Profit margin: 15% (up from 10.0% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.7% p.a. on average during the next 2 years, compared to a 2.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 12Iofina plc Provides Production Guidance for the Second Half of 2023Iofina plc provided production guidance for the second half of 2023. With the addition of IO#9 output, second half 2023 production is on track to meet the 325-350MT target.
New Risk • Jul 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (€68.5m market cap, or US$76.6m).
お知らせ • May 09Iofina plc, Annual General Meeting, Jun 14, 2023Iofina plc, Annual General Meeting, Jun 14, 2023, at 09:00 Coordinated Universal Time. Location: Canaccord Genuity, 88 Wood Street London United Kingdom Agenda: To receive and adopt the reports of the directors and the auditors and the audited financial statements of the Company for the year ended 31 December 2022; to re-appoint Malcolm Lewin as director; to re-appoint Mary Fallin Christensen as a director; to re-appoint UHY Hacker Young LLP as the Company's auditors to hold office from the conclusion of the AGM to the conclusion of the next meeting at which the accounts are laid before the Company and to authorise the directors to determine remuneration.
Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Mary Christensen was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 26Full year 2022 earnings released: EPS: US$0.041 (vs US$0.048 in FY 2021)Full year 2022 results: EPS: US$0.041 (down from US$0.048 in FY 2021). Revenue: US$42.2m (up 8.1% from FY 2021). Net income: US$7.87m (down 14% from FY 2021). Profit margin: 19% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Sep 27First half 2022 earnings released: EPS: US$0.01 (vs US$0.018 in 1H 2021)First half 2022 results: EPS: US$0.01 (down from US$0.018 in 1H 2021). Revenue: US$19.2m (down 3.8% from 1H 2021). Net income: US$1.93m (down 45% from 1H 2021). Profit margin: 10.0% (down from 18% in 1H 2021). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 1.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • May 27Iofina plc, Annual General Meeting, Jun 22, 2022Iofina plc, Annual General Meeting, Jun 22, 2022, at 09:00 Coordinated Universal Time. Location: One Bartholomew Close, London EC1A 7BL London United Kingdom
Reported Earnings • May 10Full year 2021 earnings released: EPS: US$0.048 (vs US$0.007 in FY 2020)Full year 2021 results: EPS: US$0.048 (up from US$0.007 in FY 2020). Revenue: US$39.0m (up 32% from FY 2020). Net income: US$9.19m (up US$7.91m from FY 2020). Profit margin: 24% (up from 4.3% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.3%, compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Buying Opportunity • Jan 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 3.2%. The fair value is estimated to be US$0.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% per annum over the last 3 years. The company has become profitable over the last 3 years.
お知らせ • Jan 18Iofina plc Provides Production Guidance for the First Half of 2022Iofina plc provided production guidance for the first half of 2022. For the period, the company forecasted production figure of 225-240MT of crystalline iodine.
Reported Earnings • Sep 26First half 2021 earnings released: EPS US$0.018 (vs US$0.007 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$19.9m (up 27% from 1H 2020). Net income: US$3.50m (up 164% from 1H 2020). Profit margin: 18% (up from 8.4% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 134% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 15Iofina plc Provides Production Guidance for the Second Half of 2021Iofina plc provided production guidance for the second half of 2021. For the period, the company is anticipating iodine production of 260-275 metric tonnes ("MT") , with operational changes at a brine partner's sites affecting supply levels to two of plants this year.
Reported Earnings • May 27Full year 2020 earnings released: EPS US$0.007 (vs US$0.003 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$29.7m (up 1.5% from FY 2019). Net income: US$1.28m (up 131% from FY 2019). Profit margin: 4.3% (up from 1.9% in FY 2019). Over the last 3 years on average, earnings per share has increased by 126% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Apr 15Iofina plc Revises Production Guidance for the First Half of 2021Iofina plc revised production Guidance for the first half of 2021. For the period, the company now expect production of approximately 250MT, below the 285-305 MT forecast.
